This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: The University of Texas System. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: Jonathan R. McDaniel: Innovating Cancer Immunotherapy
Introduction
Jonathan R. McDaniel, based in Austin, TX, is a distinguished inventor and researcher in the field of immunotherapy. He has made significant strides in identifying tumor-specific antibodies and T-cell receptors, contributing to the development of personalized cancer treatments. His innovative approach harnesses the power of paired mRNA sequencing, opening new avenues in cancer research.
Latest Patents
One of Jonathan’s notable patents is titled "Tumor Specific Antibodies and T-cell Receptors and Methods of Identifying the Same." This patent presents methods for identifying tumor-specific antibodies and/or T-cell receptors through paired mRNA sequencing conducted on individual immune cells within sentinel lymph nodes. These sequences are compared with mass spectroscopy data from cancer-affected subjects. His work includes novel tumor-specific antibodies, such as NY-ESO-1-binding antibodies, which hold promise for targeted cancer therapies.
Career Highlights
Jonathan R. McDaniel is affiliated with the University of Texas System, where he continues to drive innovation in cancer research. His commitment to advancing scientific understanding and therapeutic approaches has positioned him as a key player in the field. His research into tumor immunology illustrates the potential for comprehensive cancer treatment paradigms.
Collaborations
Throughout his career, Jonathan has collaborated with esteemed colleagues, including Gregory C. Ippolito and William N. Voss. These partnerships signify a collective effort towards enhancing cancer treatment strategies, demonstrating the importance of teamwork in research initiatives.
Conclusion
Jonathan R. McDaniel’s contributions to cancer research through his innovative patented methods illustrate the ongoing evolution of immunotherapy. His efforts at the University of Texas System highlight the vital role of innovation in developing new, effective treatments for cancer patients. With continued research and collaboration, the future of cancer immunotherapy looks promising.